-
Grand Pharma’s TLX591-CDx Approved for Prostate Cancer Diagnosis in China
•
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its Investigational New Drug (IND) filing for TLX591-CDx (Illuccix, gallium Ga 68 PSMA-11), a radionuclide-drug conjugate (RDC) for the diagnosis of prostate cancer, has been approved by the National Medical Products Administration (NMPA). This approval marks a significant step forward…
-
Kunshi Biotechnology Raises Angel Funding for Engineered Macrophage Platform
•
China-based Kunshi Biotechnology (Shenzhen) Co., Ltd, a company specializing in gene editing, biomaterials, and synthetic biology-driven platforms for engineered macrophages to treat solid tumors, has reportedly raised “tens of millions” of renminbi in an angel financing round. The funding was led by ASB Ventures, Riemann Hypothesis, and other investors. The…
-
Akeso Biopharma’s Cadonilimab Recommended as First-Line Treatment for Cervical Cancer
•
China-based biotech Akeso Biopharma (HKG: 9926) has revealed that its cadonilimab (AK104) has been included as the first recommended treatment for second-line recurrent or metastatic cervical cancer in the Chinese Society of Clinical Oncology’s (CSCO) cervical cancer diagnosis and treatment guidelines (2022). This marks a significant milestone in the recognition…
-
Fosun Kite’s Yescarta Gains Priority Review Status for r/r LBCL
•
China-based Fosun Kite Biotechnology Co., Ltd, a joint venture (JV) between Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) and Gilead subsidiary Kite Pharma, has revealed that Yescarta (axicabtagene ciloleucel) has obtained priority review status for adult large B-cell lymphoma (r/r LBCL) that is refractory to first-line immunochemotherapy or has…
-
Genor Biopharma Initiates First Patient Dosing for GB263T in China
•
China’s Genor Biopharma Co., Ltd (HKG: 6998) has announced the first patient dosing in a Phase I/II clinical study for its pipeline candidate GB263T in advanced non-small cell lung cancer (NSCLC) and other solid tumors in China. The drug was first administered in a first-in-human trial in Australia in May…
-
Akeso Biopharma Gains NMPA Approval for AK112 and AK119 Clinical Study
•
China-based Akeso Biopharma (HKG: 9926) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a Phase Ib/II clinical study for its AK112, a bispecific antibody (BsAb) targeting programmed death-1 (PD-1) and vascular endothelial growth factor (VEGF), in combination with its anti-CD73 monoclonal antibody (mAb) AK119 for…
-
Innovent Biologics Publishes Mazdutide Phase Ib Study Results for Obesity
•
China-based Innovent Biologics, Inc. (HKG: 1801) has announced that the results of the higher-dose cohorts in a Phase Ib study for mazdutide (IBI362), a glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist, in overweight or obese Chinese participants have been published online at eClinicalMedicine. Licensing Deal and Drug ProfileInnovent struck…
-
Sihuan Pharma to Acquire Additional Stake in Heilongjiang Duoduo Pharma
•
China-based Sihuan Pharmaceutical Holdings Group Ltd’s subsidiary, Beijing Centergate Technologies (Holding) Co., Ltd (SHE: 000931), has announced that Sihuan Pharma is set to acquire an additional 9.56% stake in Heilongjiang Duoduo Pharmaceutical Co., Ltd. Upon the deal’s closure, Sihuan will own a 78.82% stake in Duoduo Pharma, maintaining its position…
